Sponsored Content

Symrise continues strong profitable growth course

6 Feb 2025

‒ Group sales up 11.1% (organic) to €3,824 million in the first nine months, up 10.2% in the third quarter 

‒ Both segments, Taste, Nutrition & Health and Scent & Care, achieved double digit growth 

‒ Organic sales target expected to be around 7% for the full year 2024

Symrise continued its profitable growth trajectory in the first nine months of the year, achieving organic sales growth of 11.1%. Considering portfolio and exchange rate effects, Group revenue rose to €3,824 million in the first nine months (9M 2023: €3,610 million), a plus of 5.9% compared to the year-ago period. Both segments contributed to the positive development and increased sales in a global economic environment that remained challenging. In the third quarter, overall sales increased organically by 10.2%. Despite negative exchange rate effects of 4.0%, sales grew by 5.2% in the reporting currency. Against the backdrop of robust organic growth, Symrise has specified its organic growth target, sales expected to come in at around 7 %.

Jean-Yves Parisot, CEO of Symrise AG: "Symrise was able to seamlessly continue the positive business development of the past months in the third quarter. Despite the current volatile market environment due to geopolitical tensions and continued inflation pressure, we are confident for the rest of the year and expect robust demand. Our diversified portfolio and broad, international footprint will continue to help us realize our growth potential and create sustainable value this year. We are firmly convinced that we have set the right course for the future."

Sales development by region

The strongest organic growth was recorded in the Latin America region with 27.4%, followed by the Asia/Pacific region with 11.2% and EAME (Europe, Africa, Middle East) with 11.1%. The main growth drivers were the Food & Beverage, Fragrance, Aroma Molecules and Pet Food business units. The North America region achieved organic growth of 2.3%, driven primarily by the Food & Beverage and Aroma Molecules business units.

High growth in food, beverages and pet food

The Taste, Nutrition & Health segment increased sales organically by 10.4% in the first nine months of the current fiscal year. In the third quarter, organic growth was 11.3%. Taking into account portfolio and currency effects, the segment's revenue rose to €2,349 million in the first nine months (9M 2023: €2,267 million). The portfolio effect from the sale of the beverage trading business in the UK within the Food & Beverage business unit had a negative impact of € 27 million on sales development.

The Food & Beverage division achieved double-digit organic growth in percentage terms. Strong growth impulses came from the application areas for sweet and savory products and beverages. All four regions, especially the EAME region, achieved high growth. The Naturals application area increased its revenues, especially in the North America and EAME regions.

The Pet Food division also achieved double-digit organic growth in percentage terms in the first nine months. Sales development was particularly dynamic in the Asia/Pacific and Latin America regions, with double-digit organic growth.

Sales development in the Aqua Feed business unit recorded declining organic growth. As part of the further portfolio streamlining with a focus on high-margin growth areas, Symrise intends to sell the business.

The probiotics business, which includes the majority stake in the listed company Probi AB, Lund, Sweden, generated slight growth, driven by the EAME region.

Symrise continues strong profitable growth course
Image courtesy of Symrise AG

Strong sales growth in Consumer Fragrance and significant recovery in Aroma Molecules

The Scent & Care segment, which manages the fragrances, perfumery applications and cosmetic active ingredients business, achieved organic sales growth of 12.2% in the first nine months and 8.4% in the third quarter respectively. Taking into account portfolio and currency effects, revenue for the first nine months amounted to €1,475 million (9M 2023: €1,343 million).

The Fragrance division increased its sales organically in the double-digit percentage range in the first nine months. In particular, the Consumer Fragrance application area achieved double-digit percentage growth. The EAME, Asia/Pacific and Latin America regions in particular experienced very high market dynamics. The Fine Perfumery application area also continued its very positive development and achieved high single-digit percentage organic growth. Here, the Latin America and Asia/Pacific regions recorded good growth. The Oral Care application area achieved single-digit percentage organic growth, with good growth especially in the North America and Asia/Pacific regions.

Sales in the Aroma Molecules division recovered significantly in the first nine months of the current year. While the market environment continues to prove challenging, the resumption of production in Colonels Island, USA has resulted in a significant year-on-year increase in revenue. High double-digit growth figures were achieved in all regions.

Sales in the Cosmetic Ingredients division continued to develop strongly with high single-digit percentage organic growth. Revenues increased significantly in the EAME, Asia/Pacific and Latin America regions. Only the North America region showed just a slight year-on-year growth. The application areas for micro-protection and actives and botanicals also recorded very strong growth impulses.

Symrise specifies growth target for 2024

Based on the good business performance in the first nine months, Symrise is specifying its sales target for the full year 2024. The Group is now aiming for organic sales growth of around 7%. The Group's long-term organic growth expectation of 5% to 7% (CAGR) remains unchanged. The long-term EBITDA margin is expected to be in the range of 20% to 23%.

Read More

Related categories

Related tags

Sponsored Content

Related news

PharmaLinea’s iron supplement delivers improvements in  hemoglobin comparable to ferrous sulfate with fewer side  effects

PharmaLinea’s iron supplement delivers improvements in hemoglobin comparable to ferrous sulfate with fewer side effects

23 Feb 2026

PharmaLinea, a Slovenian developer and manufacturer of private label food supplements, has announced the completion of a clinical study evaluating its finished formulation for iron deficiency.

Read more 
LomaChelateX® – power in magnesium bisglycinate

LomaChelateX® – power in magnesium bisglycinate

12 Feb 2026

Gentle and effective: magnesium bisglycinate is setting a new standard. Through its LomaChelateX® brand, Dr. Paul Lohmann® delivers magnesium bisglycinate and a broad range of fully reacted mineral bisglycinates made in Germany.

Read more 
Fucoidan leader reports record production

Fucoidan leader reports record production

22 Jan 2026

The global leader in fucoidan science, Marinova Pty Ltd, reported record annual fucoidan production for 2025. The company's total production volume has more than doubled over the past three years.

Read more 
India Honours Ashwagandha with Commemorative  Postal Stamp at WHO Global Summit

India Honours Ashwagandha with Commemorative Postal Stamp at WHO Global Summit

6 Jan 2026

HYDERABAD, December 20, 2025 – India’s Prime Minister Mr. Narendra Modi, alongside WHO Director-General Dr. Tedros Adhanom Ghebreyesus, released a commemorative postal stamp honoring ashwagandha at the recently concluded Second WHO Global Traditional...

Read more 
PharmaLinea delivers actionable 2026 insights at the first ever NutraLoop™ Summit

PharmaLinea delivers actionable 2026 insights at the first ever NutraLoop™ Summit

22 Dec 2025

PharmaLinea held its first-ever NutraLoop™ Summit this December. The virtual event featured 12 speakers from companies such as IQVIA, NHCO, Radicle Science, and BeyondBrands, who provided comprehensive insights across the scientific and commercia...

Read more 
FrieslandCampina strengthens its global protein position with acquisition of Wisconsin Whey Protein

FrieslandCampina strengthens its global protein position with acquisition of Wisconsin Whey Protein

11 Dec 2025

Royal FrieslandCampina N.V. intends to acquire Wisconsin Whey Protein, a respected producer of whey protein isolates in the United States. Wisconsin Whey Protein will become part of FrieslandCampina Ingredients, a global leader in proteins and prebioti...

Read more 
dsm-firmenich names ‘Frosted Star Anise’ as Flavor of the Year 2026, capturing a global desire for warmth and freshness

dsm-firmenich names ‘Frosted Star Anise’ as Flavor of the Year 2026, capturing a global desire for warmth and freshness

11 Dec 2025

Kaiseraugst (Switzerland), Maastricht (Netherlands), December 5, 2025  dsm-firmenich, innovators in nutrition, health, and beauty, announces ‘Frosted Star Anise’ as its Flavor of the Year for 2026. This...

Read more 
Balchem Makes Strategic Investment in U.S. Food Ingredients Market with New Microencapsulation Manufacturing Facility

Balchem Makes Strategic Investment in U.S. Food Ingredients Market with New Microencapsulation Manufacturing Facility

11 Dec 2025

Montvale, New Jersey, (10 December, 2025) – Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health, is pleased to announce the development of a new, high-capacity man...

Read more 
Fucoidan specialist takes out top international health award

Fucoidan specialist takes out top international health award

4 Dec 2025

Marinova has been named Australia's most outstanding contributor to international health in the nation's prestigious Australian Export Awards.

Read more 
Prayon inaugurates its new SHMP production unit in Engis

Prayon inaugurates its new SHMP production unit in Engis

1 Dec 2025

Prayon inaugurates its new SHMP production unit in Engis, a major investment that strengthens its position in the food and technical phosphates market

Read more